Strata Skin Sciences Inc.

Strata Skin Sciences Inc. is a healthcare company that specializes in innovative dermatological technologies aimed at treating skin conditions through advanced medical devices and solutions. Strata Skin Sciences Inc. operates in the dermatology field, focusing on the development of advanced treatments for skin conditions.

Founded in 1989 and headquartered in Horsham, US, the company has undergone major changes in its business strategy, including a recent focus on innovative product offerings. CEO Robert Moccia leads the company, which has secured a total of USD 17. 00 mn in funding, culminating in the latest PIPE funding round on July 6, 2023, led by Accelmed. Notably, the company has undertaken 2 deals since its inception.

Strata Skin Sciences specializes in advanced dermatological technologies, focusing on innovative products designed to treat various skin conditions. Their core offerings include the XTRAC excimer laser and the TheraClear® X system. The XTRAC laser delivers a targeted therapeutic beam of UVB light to treat psoriasis and vitiligo, providing a quick and virtually painless alternative to traditional treatments. TheraClear® X employs photopneumatic technology, combining vacuum and broadband light to effectively address mild-to-moderate acne.

These products are utilized by dermatology, plastics, and aesthetics professionals, serving a diverse client base that includes healthcare providers and their patients. Strata Skin Sciences markets its solutions across various geographical regions, including North America and select international markets. In 2021, Strata Skin Sciences generated revenue of USD 29. 98 mn, with an EBITDA of USD -0.

28 mn. The company generates revenue through direct sales of its dermatological products to healthcare providers and professionals, primarily on a B2B basis. Transactions typically involve one-time purchases for equipment and disposable components used during treatment sessions, with ongoing service and maintenance partnerships. The XTRAC laser and TheraClear® X system are central to their offerings, emphasizing their commitment to delivering effective skin treatment solutions.

Strata Skin Sciences plans to enhance its product line with upcoming innovations in dermatological technology, although specific new product details and launch dates have not been disclosed. The company seeks to expand into new markets, particularly looking at increased penetration in North America and select international regions by 2024. The recent PIPE funding round of USD 17. 00 mn will be directed towards strengthening the company’s balance sheet and supporting its refinancing activities, thereby providing a solid foundation for future growth initiatives.